

## Long term use of Carglumic acid in patients with propionic and methylmalonic acidemia

K. Elrififi, M. Fares, A. Alshah Children hospital/Tripoli

### Abstract

**Objective:** to evaluate the clinical long term use of carglumic acid in cases of propionic and methylmalonic acidemia

**Materials and Methods:** 13 patients diagnosed as PA, MMA at children hospital who are less than 2 years of age with no or minimal brain damage started on carglumic acid 50mg/kg/d divided 12h for at least 3 months were included in this study. Information's were gathered from their medical files at Metabolic OPD during their regular visits and from medical files at paediatric/ ICU admissions if they encountered an acute crisis. Growth parameters, developmental assessment and frequency of admission due to crisis after treatment initiation were studied. In acute decomposition mean ammonia level, biochemical and haematological parameters and mean hospital stay were also observed.

**Results:** 13 patients included in this study 8 propionic acidemia and 5 methylmalonic acidemia, started on Carglumic acid 50mg/kg/d for a period 3 to 9 months, 3 patients were admitted with metabolic decompensation, with average 2 days hospitalization. **Conclusion:** obvious decrease in no. Of hospitalizations due to metabolic decompensation as well as decrease in duration of hospital stay was noted in treated patients, Carglumic acid is well tolerated with no obvious side effects.

Key words: Carglumic acid, propionic acidemia, methylmalonic acidemia

### Introduction:


Propionic acidemia (PA), is a rare metabolic disorder inherited as an autosomal recessive disorder of amino acid and odd-chain fatty acid metabolism, was initially described in 1961, this disease characterized by elevations in glycine in both plasma and urine (1,2). In 1969 Hsia et al. were the first who note that there is defective propionate oxidation which is due to Propionyl-CoA carboxylase (PCC) deficiency. This PCC enzyme catalyse the

conversion of propionyl CoA to malonyl CoA in the mitochondria. Its incidence vary it is more frequent in Saudi Arabia 1 in 2000-5000 live births while in other countries it range from 1 in 50000-100000 (9,10) For methylmalonic acidemia it is from 1:50-100000 live births. 1970 Gompertz et al. describe enzyme deficiency in hepatocytes, and one year after Hsia et al. describe also enzyme deficiency in fibroblasts (3-5). Brandt et

al. in 1974 start treating these disorders with protein restriction(6). Propionic both associated with life threatening episodes of hyperammonemia and metabolic acidosis (metabolic crisis) which may cause serious neurological sequels. Neurological complications in PA include seizures which take different forms like generalized tonic-clinic, focal (with or without generalization), myoclonic, and atonic seizure. Other neurological complication of prop ionic academia's basal ganglia abnormalities associated with extrapyramidal movement disorders and brain atrophy (7), these neurological abnormalities may be due to cerebrospinal fluid elevations in lactate and ammonia. There is also elevated lactate, glutamine, glycine, and alanine were detected in a patient with neurological symptoms but no signs of catabolism. In the year 2000 Chemelli et al describe elevations in brain lactate level (lactate peak) on magnetic resonance spectroscopy (8) Other systemic

**Metabolic pathway:**

and methylmalonic acidemia involvement is Bone marrow suppression seen usually in severe metabolic crisis manifested by pancytopenia which occurs in some patients during early presentation of the disease (10-12). More rarely is the occurrence of acute pancreatitis (13). Other rare complication as Cardiac complications may occur in prop ionic academia as dilated cardiomyopathy, arrhythmias and long QTC interval(9) Carglumic acid is a structural analogue of N acetylglutamate which is a naturally occurring and selective activator of carbamyl phosphate synthetase. It enhances ammonia detoxification through activation of urea cycle and increase in urea genesis. It is approved in EU since 2003 for treating high ammonia in NAGAS deficiency and in 2014 in USA for treating acute hyperammonemia in organic acidemia (14,15)



#### Materials and methods:

A prospective clinical study of 13 patients who are diagnosed as PA and MMA at Children hospital/ Tripoli. Inclusion criteria: patients who are less than 2 years of age with no or mild brain damage are included in this study also another 2 patients more than 2 years of age were included as they have multiple admissions with reasonable development and multiple deaths in their families. Patients started on Carglumic acid 50mg/kg/d divided 12 h. These patients are already started on protein restricted diet (0.5-1g/kg/day), also L carnitine 50-100g/kg/d divided 12 hourly, metronidazole 10mg/kg/d alternate day and tonics since diagnosis was made. Data were collected from patients medical files at our out

#### Results

- 13 patients started on treatment, 8 males and 5 females
- 8 patients have PA, of them 5 males and 3 females
- 5 patients have MMA, 3 males and 2 females
- Age at diagnosis range from 1 wk-15m, mean 292 days
- 12 patients have early presentation before 2 months of age,
- 6 patients diagnosed in neonatal period, other 7 patients diagnosed later all of them have an early presentation and admitted before to hospital

patients clinic, for those who had acute crisis data collected from medical files at ICU / word. The patients were seen monthly at our follow up clinic Data including clinical examination, growth parameter, and developmental assessment, cardiological work up (ECG and echocardiography) is also done before and after starting carginic acid, parents also asked to report any unusual problem during treatment. For patients admitted with acute crisis mean ammonia levels, biochemical investigations, and also duration of hospital stay were observed. Monthly CBC, biochemistry, LFT, Renal function and lipid profile were done for all patients.

Patient & diagnosis	Age at Treatment Start	Age at diagnosis	Sex	Duration of treatment	No. crisis before treatment	No. crisis after treatment
---------------------	------------------------	------------------	-----	-----------------------	-----------------------------	----------------------------

1- PA	21days	21days	M	6m	1	No
2- PA	11m	1 m	F	5m	5	No
3 -MMA	8days	8days	M	4m	1	No
4 -MMA	22days	22days	F	3m	2	No
5- PA	16m	42days	M	4m	2	No
6- PA	13m	6m	M	3m	2	No
7 -PA	5m	5m	M	5m	3	No
8-MMA	3m	2m	F	6m	2	No
9-MMA	2y	16m	F	3m	3	1
10-PA	6m	6m	M	6m	4	No
11-MMA	2y6m	1m	F	3m	10	No
12-PA	15m	15m	M	2m	9	1
13-PA	2y4m	21days	M	9m	10	2

PA=propionic academia MMA= methylmalonic academia m=months

Average time for treatment with Carglumic acid is 4.5months (range 2-9months)

5 patients started on Carglumic acid immediately after diagnosis as they were admitted with metabolic crisis and continued on it (received 3-6m), these patients were admitted with metabolic crisis and Carglumic acid was given initially at high dose 200mg/kg/d then decreased to 50mg/kg/d after crisis passed and continued on this dose.

**No. of admissions (metabolic crisis) before and after starting Carglumic acid:** 7 Patients with early presentation (before 2 months of age) all except for one had at least one admission before diagnosis average 4 admissions before diagnosis of propionic and or methylmalonic was made, no one had admission during treatment with Carglumic acid

**Duration of hospital stay before and after treatment:** average one week (7-10days) before, 2 days after treatment with Carglumic acid

Weight gain during treatment average 0.3 kg/ month for those <1 year of age.

**3patients out 13 have crisis during treatment with Carglumic acid**

1-Patient number 1 is a Male 4 y+9m diagnosed in neonatal period as propionic academia, family had 3died non diagnosed children, 2 live females, this patient had 10 times admissions because of multiple crisis of hyperammonemia, 5 of them in the year 2015 all in ICU, he is on protein restriction of 0.6g/kg/day this patients had twice admissions during treatment with Carglumic acid (pneumonia), serum Ammonia was mildly elevated 90-100,

received 9 months Carglumic acid, average hospital stay 2 days. This patient is always sick with too frequent OPD visits, extensive investigations for the possible immune deficiency including viral screen (HIV, TOCHS), immunoglobulin and T- cell functions were all normal.

2-The 2<sup>nd</sup> patient is a Female 3 years old had 10 admission before and always sick, family has another healthy female child and another died child with the same diagnosis. She has normal development,

**Carglumic acid side effects:** only in one patient loose motions were noted by the mother during Carglumic acid treatment.

### **Discussion:**

Hyperammonemia is an emergency situation mostly due to genetic metabolic disorders. One of the most causes of hyperammonemia are urea cycle disorders and organic acidemia. If left untreated it cause neurotoxicity and irreversible brain damage (16-18), patients with propionic acidemia have life treating episodes of hyperammonemia ( metabolic crisis) as well as intellectual disability also poor growth and stroke episodes of basal ganglia (19).

The administration of N-carbamylglutamate (Carglumic acid) has

was admitted with acute tonsillitis after treatment with Carglumic acid, ammonia was normal during admission, this patient received 3 months Carglumic acid.

3-The 3<sup>rd</sup> patient is a Female 16 months old admitted 3 times before one of them in ICU, this patient admitted with severe GE, hypoglycaemia, and dehydration after starting Carglumic acid. Ammonia was mildly elevated, admitted for 2 days, this patient received treatment only for 3 months.

None of our patients had Cardiological problems before or after starting of treatment with Carglumic acid.

been reported to be of benefit in many conditions associated with hyperammonemia, both propionic and methylmalonic acidemia are complicated with hyperammonemia due to inhibition of Carbamyl phosphate synthesis ( first step in urea cycle) leading to reduced synthesis of N-acetylglutamate synthase (NAS) leading to defective ammonia formation (20,21)

Gebhardt, et al were the first who treated patients with hyperammonemia due to Propionacidemia with Carglumic acid in acute decompensation and found a

significant increase in ammonia detoxification (22) Carglumic acid is a new drug manufactured by Orphan Europe Company was initially used to treat hyperammonemia due N-acetylglutamate synthase deficiency (urea cycle disorder). In 2003 first trial of its use in 2 cases one propionic and the 2<sup>nd</sup> case methylmalonic acidemia. It was used to treat acute hyperammonemia in these cases. It has been proven that Carglumic acid when used with or without ammonia scavengers is an effective to restore normal plasma ammonia in hyperammonemic episodes in organic acidemia patients. There are many published guide lines for the use of Carglumic acid in propionic and In our hospital we have 34 patients diagnosed as propionic and methylmalonic acidemia, 28 patients have propionic acidemia (16 alive, 12 died) and 5 patients have methylmalonic acidemia (4 alive and 1 died), these patients have frequent crisis due to viral infections or after vaccinations, and it is the most common cause for admission among inborn errors of metabolism in our hospital (personal observation).

Our patients have high mortality 50% due probably to disease severity and late diagnosis of the disease as there is no national new born screening in Libya yet. All our patients were presented with metabolic crisis at the time of diagnosis.

methylmalonic acidemia during acute decompensation (crises) (23-25) Long term studies of its use for propionic acidemia are still going on in Saudi Arabia where the disease is common 1: 2500 populations but not yet published (26-28). There is a recent published study which is similar to ours (29) and the authors found a decrease in both in number and severity of metabolic crisis in propionic acidemia although the age group in this study is not similar to ours, as in this study 6 patients their age from 5-22 years and only 2 patients are less than 5 years. There is no previous study about propionic and methyl malonic acidemia in Libya.

Mild hyperammonemia sometimes is not recognized by mothers caring such children's at home, these children when started on long term Carglumic acid 50mg/kg/d divided 12 hourly We observed that there was a significant reduction of admissions comparing to before ( only 3 patients out of 13 had been admitted in crisis) this may be due to effect of Carglumic acid in decreasing ammonia level which is sometimes raised in the presence of mild upper respiratory infection and prevent the subsequent development of metabolic crises.

During the treatment no major side effects were noted by parents, only one mother noted loose stool.

Although this observation is an important one but we could not do this study for a longer period as Carglamic acid is an expensive medication and also the amount available is not enough to give it for a longer periods.

Long periods of studies are essential to clarify long term use of Carglamic acid in decreasing the frequency of metabolic crises and also its side effects.

## References

- 1-Childs B, et al , idiopathic hyperglycinemia and hyperglycinuria: a new disorder of amino acid metabolism 1, *Pediatrics* 27 (1961) 522-538
- 2- Nyhan W.L, Borden, M, Childs B, idiopathic hyperglycinemia: a new disorder of amino acid metabolism. 11, the concentration of other amino acids in plasma and their modification by the administration of leucine, *Pediatrics* 27 (1961) 539-550
- 3-Hsia Y.E, Scully K.J, Rosenberg LE, defective propionate carboxylation in ketotic hyperglycinemia, *Lancet* 1 (1969) 757-7748
- 4-Gomertz D, et al, localization of enzymic defect in propionic academia, *Lancet* 1 (1970) 1140-1143
- 5- Hsia Y.E, Scully K.J, Rosenberg LE, Inherited propionyl COA carboxylase deficiency in ketotic hyperglycinemia, *J Clin. Invest.* 50 (1971) 127-130
- 6- Brandt Lk, et al, propionic academia (ketotic hyperglycinemia): dietary treatment resulting in normal growth and development, *Pediatrics* 53 (1974) 391-395
- 7-Harber Landt, et al, Epilepsy in patients with propionic acidemia, *Neuropediatrics* 40 (2009) 120-125
- 8-Chemelli, Magnetic resonance spectroscopy (MRS) in five patients with treated propionic academia *J Magn Resn Imaging* 2000 (6): 596-6000
- 9-D. Baumgartner, et al Prolonged QTC intervals and decreased left ventricle contractility in patients with propionic acidemia, *J Pediatr.* 150 (2007) 192-197
- 10-S. Muller, et al, Propionic acidemia and immunodeficiency, *Lancet* 1 (1980) 551-552
- 11-LC Strok, et al Pancytopenia in Propionic acidemia, haematological evaluation and studies in haematopoiesis in vitro, *Pediatr Res*;20 (1986) 783-788
- 12- T.Sipahi, D.Yilmaz, B. Tavit, Propionic acidemia with Myelodysplasia and neutropenia in a Turkish child, *J Pediatr Haematol. Oncol*; 26 (2004) 154-155
- 13-G. Bultron, et al Recurrent acute Pancreatitis associated with Propionic academia, *A J Med Gent, A* 146A (2008) 3090-3090
- 14-Valayannpolous V, et al Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favorable risk-benefit profile: a retrospective observational study, *Orphanet J Rare disease* (2016), 11:32



- 15- Albacan M, Boneh A Use of carginic acid in the treatment of hyperammonemia during metabolic decompensation of patients with propionic acidemia, Mol Genet Metab (2014): 4, Vol 109, 397-401.
- 16-MCC Machudo, et al, Hyperammonemia due to urea cycle disorder, a potentially fatal condition in the intensive Care setting, J Intens Care; 2 (2014), 4
- 17-HJ Yoon, Devastating Metabolic Brain disorders of Newborn and young infants Radio Graphs(2014), Vol 37, No.2
- 18-P Jafari, et al, Brain damage in Methylmalonic acidemia: 2-methyl citrate induces cerebral ammonium accumulation and apoptosis in 3 D organotypic brain cell cultures, Orphanet J Rare disease (2013) 8; 4
- 19-MR Baumgartner, et al Proposed guidelines for the diagnosis and management of methylmalonic and Propionic acidemia, Orphanet J Rare disease (2014) (; 130
- 20-M Daniotti, New development in the treatment of hyperammonemia, emerging use of Carginic acid, Int J Gen Med (2011) 4, 21-28
- 21- Bachmann, et al, N-acetylglutamate synthetase deficiency: a disorder of ammonia detoxification N Engl J Med (1981) 9; 1543
- 22-Gebhardt B, et al, N-Carbamylglutamate protects patients with decompensated Propionic acidemia from hyperammonemia J Inher Metab Dis (2005); 28 (2) 241-244
- 23-Baumgartner MR, proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia, Orphanet J rare Dis, 2014, 9,130
- 24-Chapman, Acute management of propionic acidemia, <https://www.ncbi.nlm.nih.gov>
- 25-Rafique M, Emerging trends in management of propionic acidemia, [www.scielo.br/scielo](http://www.scielo.br/scielo)
- 26 –MoammarH , et al incidence and pattern of inborn error of metabolism in the Eastern Province of Saudi Arabia, 1983-2008, (2010) Ann. Saudi Med. 30, 271-277
- 27-M.Tuchmann, et al, long term outcome of N carbamylglutamate treatment in Propionic and methylmalonic acidemia, Clinical Trials.gov.(2015)
- 28-Alfadhel, M, Carginic acid in methylmalonic acidemia and propionic acidemia, Clinical Trials.gov. (2017)
- 29- Burlina A, et al , Clinical experience with N Carbamylglutamate in a single-center Cohort of patients with propionic and methylmalonic aciduria, Mol Genet & Metab Reports (2016), vol 11